临床试验/NCT00858572

NCT00858572已完成1 期

A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies

Synta Pharmaceuticals Corp.0 个研究点目标入组 31 人开始时间: 2009年3月最近更新: 2014年9月18日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Synta Pharmaceuticals Corp.
入组人数: 31
主要终点: To assess preliminary evidence of anti-neoplastic activity

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究组 & 干预措施

Cohort

Experimental

干预措施: STA-9090 (ganetespib) (Drug)

结局指标

主要结局

To assess preliminary evidence of anti-neoplastic activity

时间窗: Feb 2011

To assess the pharmacokinetics of STA-9090 (ganetespib) when administered as a short-term intravenous infusion

时间窗: Feb 2011

To characterize the safety and tolerability of STA-9090 (ganetespib) in subjects with hematologic malignancies

时间窗: Feb 2011

次要结局

To investigate drug exposure levels/plasma concentrations and correlations with efficacy and safety parameters(Feb 2011)
To assess the impact of variations in drug metabolizing enzymes (DME pharmacogenomics) on the pharmacokinetics of STA-9090 (ganetespib)(Feb 2011)
To assess changes in biomarkers following study drug administration(Feb 2011)

研究者

发起方

Synta Pharmaceuticals Corp.

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

1 期

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous LeukemiaBlast-phase Chronic Myelogenous LeukemiaALLCMLAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaAML

NCT00964873Synta Pharmaceuticals Corp.29

Unknown

1 期

Study of STA-9090, Administered Twice-Weekly in Patients With Solid TumorsSolid Tumors

NCT00688116Synta Pharmaceuticals Corp.45

已完成

1 期

Study of STA-9090, Administered Once-Weekly in Patients With Solid TumorsSolid Tumors

NCT00687934Synta Pharmaceuticals Corp.53

已完成

2 期

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)Non Small Cell Lung Cancer

NCT01031225Synta Pharmaceuticals Corp.113

已完成

1 期

STA-9090 in Patients With Advanced Hepatocellular CancerHepatocellular Carcinoma

NCT01665937Massachusetts General Hospital16